Novartis
NEWS
Artios Pharma Limited, based in Cambridge, U.K., got a significant financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding that will help advance its DNA Damage Response (DDR) programs for cancer treatments.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
As Britain’s “Brexit” from the European Union moves closer and closer, the European Medicines Agency (EMA), the equivalent to the U.S. Food and Drug Administration (FDA), temporary halted some of its activities in preparation.
Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Before taking over the helm of Novartis AG, Vasant Narasimhan pointed to the harnessing of digital technology as a key method of saving a significant percentage of clinical trial costs.
Boston-based resTORbio, which was spun out of Novartis in April 2017, announced positive topline results from its Phase IIb clinical trial of RTB101 in patients with respiratory tract infections (RTIs).
JOBS
IN THE PRESS